Angina Pectoris Drugs Market Growth Forecast: Exploring Trends and Opportunities for the Next Decade
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What key factors are powering the surge in the angina pectoris drugs market right now?
Over the past few years, the angina pectoris drugs market size has seen significant growth. The market, which is projected to expand from $12.32 billion in 2024 to $12.94 billion in 2025, will experience a compound annual growth rate (CAGR) of 5.1%. Historical growth in this market has been influenced by several factors, such as the widespread occurrence of cardiovascular diseases, an aging population, lifestyle-related factors, a rise in hypertension rates, and increasing prevalence of diabetes.
How fast Is the angina pectoris drugs market expected to grow, and what’s its future value?
The market size for drugs treating angina pectoris is projected to witness significant growth in the upcoming years. By 2029, it is expected to reach “$16.55 billion, with a compound annual growth rate (CAGR) of 6.3%. The anticipated growth during the forecast period is largely due to the increasing obesity rates worldwide, advancements in precision medicine, preventive cardiology focus, initiatives to educate patients, and research into new therapeutic targets. Key trends during the forecast period are likely to include remote patient monitoring via telemedicine, studies based on real-world evidence and outcomes, education centered around patient medication, strategic alliances for better market reach, regulatory progress, and fast-tracked approvals.
Get your angina pectoris drugs market report here!
https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report
What are the leading drivers of growth in the angina pectoris drugs market?
The growth of the angina pectoris drug market is projected to be propelled by the rising occurrences of cardiovascular diseases. These diseases, which impact the heart and blood vessels, include a wide spectrum of ailments such as coronary artery disease, high blood pressure, heart failure, and stroke. Factors contributing to the increased prevalence of cardiovascular diseases include an aging population, unhealthy lifestyles, and an obesity epidemic. Effective chest pain relief, brought about by inadequate blood flow to the heart, is provided by angina pectoris drugs like nitrates, beta-blockers, and calcium channel blockers, thus improving patients’ overall quality of life. As per the data released by the British Heart Foundation, a cardiovascular research charity from the UK, in September 2024, approximately 7.6 million people in the UK suffer from heart and circulatory diseases, with about 4 million males and 3.6 million females affected. These conditions account for roughly 27% of all deaths in the UK, leading to over 170,000 deaths each year, or about 480 deaths daily, which is equal to one death every three minutes. Consequently, the rising prevalence of cardiovascular diseases is fueling the expansion of the angina pectoris drug market.
What are the key segments defining the angina pectoris drugs market?
The angina pectoris drugs market covered in this report is segmented –
1) By Drugs: Nitrates, Antiplatelet Agents, Beta-adrenergic Blocking Agents, Calcium Channel Blockers, Anti-ischemic Agents, Statins, Antihypertensive Agents, Other Drugs
2) By Indication: Stable Angina, Unstable Angina, Prinzmetal’s Angina
3) By Route of Administration: Oral, Parenteral, Transdermal, Other Route Of Administrations
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Nitrates: Short-Acting Nitrates, Long-Acting Nitrates
2) By Antiplatelet Agents: Aspirin, Clopidogrel
3) By Beta-Adrenergic Blocking Agents: Non-Selective Beta Blockers, Selective Beta Blockers
4) By Calcium Channel Blockers: Dihydropyridine Calcium Channel Blockers, Non-dihydropyridine Calcium Channel Blockers
5) By Anti-Ischemic Agents: Ranolazine, Ivabradine
6) By Statins: Atorvastatin, Rosuvastatin
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10797&type=smp
Who are the key players steering the development of the angina pectoris drugs market?
Major companies operating in the angina pectoris drugs market include Astellas Pharma Inc., Bayer AG, Novartis AG, AstraZeneca PLC, Bausch Health Companies Inc., Merck & Co Inc., Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, Sun Pharmaceutical Industries Limited, Sanofi SA, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Johnson & Johnson, AERIE PHARMACEUTICALS INC., AbbVie Inc., Amgen Inc., Gilead Sciences Inc., GlaxoSmithKline plc, H. Lundbeck A/S, Ipsen S.A., Lupin Pharmaceuticals Inc., Merck KGaA, Otsuka Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Servier Laboratories, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A.
What emerging trends are influencing the growth of the angina pectoris drugs market?
Product development is an emerging trend in the angina pectoris drugs marketplace, with many major firms adopting innovative techniques to maintain their market standing. For example, Hikma Pharmaceuticals PLC, a British pharmaceutical corporation, introduced a new product, Labetalol Hydrochloride Injection, USP, in a prefilled syringe, in March 2023. The U.S. Food and Drug Administration (FDA) has formally approved this product. It’s most frequently used in hospitals, where a 10 mg/2 mL PFS dosage is administered to treat severe hypertension and reduce blood pressure.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10797
Which regions are most influential in expanding the angina pectoris drugs market?
North America was the largest region in the angina pectoris drugs market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the angina pectoris drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Alzheimer’s Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report
Generic Central Nervous System Drugs Global Market Report 2024
Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
